Serina Therapeutics (NYSEAMERICAN:SER) Director Purchases $17,700.00 in Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Karen Wilson purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were purchased at an average price of $1.77 per share, for a total transaction of $17,700.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at $17,700. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Serina Therapeutics Stock Performance

Serina Therapeutics stock opened at $1.95 on Friday. Serina Therapeutics, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $7.92. The stock has a market capitalization of $29.25 million, a PE ratio of -0.98 and a beta of 1.15. The stock’s 50-day moving average price is $1.98. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24.

Serina Therapeutics (NYSEAMERICAN:SER) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.